Even though it is widely accepted that angiotensin II (Ang II) primarily activates two receptor subtypes, the angiotensin type 1 receptor (AT1R) and angiotensin type 2 receptor (AT2R), our understanding of the functional significance of AT2R has not kept pace with that of AT1R, on which voluminous work has been done. 1,2 It has been well documented that AT1R mediates the majority of Ang II effects in both physiological and pathological conditions. These include the regulation of sympathetic outflow and cardiovascular function, water and electrolyte balance, thirst, and hormone secretion. 3, 4 The AT2R, on the other hand, has long been viewed as having its major function during the early stages of development and growth of animals, in view of its ubiquitous expression at very high levels in the fetus and its rapid regression to low levels shortly after birth. 1,2 This limited view of the role of AT2R has dampened the enthusiasm to explore this receptor's function, especially in adult animals.
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The results of some studies, however, consistently imply that the role of AT2R is of physiological significance. For example, in vitro experiments demonstrated that AT2R stimulation increases potassium current (I Kv ), thereby decreasing neuronal excitability. 5, 6 Siragy et al. 7 reported that AT2R-null mice had slightly elevated systolic blood pressure (BP) as compared to wild-type control mice, and that infusion of a subpressor dose of Ang II induced no change in the BP in wild-type mice whereas it significantly increased the BP in AT2R knockout mice. Moreover, Li et al. 8 found that injection of Ang II into the cerebral ventricle evoked a larger increase in BP in AT2R knockout mice as compared to wild-type mice. These investigators further demonstrated that, in wild-type mice, central injection of Ang II plus the AT2R antagonist PD123319 initiated a greater pressor response than the one induced by Ang II alone. These results suggest that AT2R has a negative influence on neuronal function and cardiovascular activity, which opposes the stimulating effect of AT1R. Indeed, we recently original contributions Central AT2 Receptors and Sympathetic Outflow found that AT2R protein expression was significantly downregulated in the rostral ventrolateral medulla (RVLM) of rats with chronic heart failure, and that this decrease in AT2R expression played a critical role in sympathoexcitation in this syndrome. 9 In conscious, normal rats, on the other hand, overexpression of AT2R in the RVLM evoked a transient but significant decrease in arterial blood pressure (AP) and excretion of norepinephrine (NE). 10 Interestingly, recent findings from our laboratory clearly demonstrate that, in the brainstem, liver, and kidney of adult rats, AT2R protein expression is significantly higher than in the corresponding tissues of fetuses and neonates, 11 thereby suggesting that AT2R may have a function not only in early life but also in adulthood.
Compound 21 (C21) is a recently created nonpeptide AT2R agonist which is metabolically stable, is effective when administered orally, and has potential therapeutic efficacy. 12 C21 has been shown to have beneficial effects in animal models of hypertension and myocardial infarction when administered systemically. 12, 13 Moreover, C21-evoked dose-dependent vasorelaxation in isolated aortic and mesenteric vessels. 14 However, there have been no reports regarding its effects on the central nervous system, sympathetic outflow, and AP in animals. In this experiment, we hypothesized that central administration of C21 would have sympatho-inhibitory and depressor effects. We therefore determined the influences of central administration of C21 on NE excretion and AP in conscious normal rats.
Methods
Animal experiments. In this experiment, 35 male SpragueDawley rats of weights ranging between 290 and 380 g were used. All the experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of Nebraska Medical Center, and were carried out under the guidelines of the American Physiological Society and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Under isoflurane anesthesia, the rats were implanted with radiotelemetry devices (model TA11PA-C40, Physiotel; Data Sciences International, St Paul, MN), which were secured in the inguinal area. The sensing catheter was inserted into the left femoral artery, against the direction of blood flow, for the purpose of measuring the values of pulsatile and mean arterial blood pressure (MAP).
The rats were randomly assigned to one of four groups to receive four different reagents. Each of the anesthetized rats was placed in a stereotaxic frame (Stoelting Instruments, Wood Dale, IL). The skull was exposed through a midline scalp incision. A small burr hole was made above the right cerebral ventricle (coordinates: 0.8 mm posterior to the bregma and 1.5 mm lateral from midline). ALZET Brain Infusion Kits and 1007D Micro-Osmotic Pumps (ALZET Osmotic Pumps; DURECT, Cupertino, CA) were used for the intracerebroventricular (icv) infusion of the appropriate reagent for 7 days. The four groups were: vehicle control group (artificial cerebrospinal fluid 1 µl/h), C21 (0.5 µg/µl/h) group, C21 (0.5 µg/µl/h) + PD123319 (0.5 µg/µl/h) group, and C21 (0.5 µg/µl/h) + N-omega-nitrol-arginine methyl ester (l-NAME, 50 µg/µl/h) group. C21 was a gift from Vicore Pharma AB (Goteborg, Sweden). PD123319 and l-NAME were purchased from Sigma-Aldrich (St Louis, MO).
After the surgery, each of the rats was placed in a metabolism cage for the collection of urine, and at that time point the AP was also recorded. The urine was collected twice a day: at 8:00 am (night urine) and at 8:00 pm (day urine), and frozen (−80 °C) until analysis for NE.
Urinary NE was measured using a Norepinephrine Enzyme Immunoassay kit (Labor Diagnostika Nord KG, Nordhorn, Germany). A 50-µl urine sample from each of the animals was diluted with 950 µl double-distilled H 2 O to obtain a 20:1 dilution, from which 10 µl was used for NE measurements in accordance with the instructions provided by the company. Duplicate measurements were made for each sample. NE excretion was determined by multiplying the urinary NE concentration by the volume of urine collected over 12 h. The data are expressed as µg/12 h.
MAP was recorded 10 min/h for 24 h/d, using a macroprogram written for Chart (version 5.4.2) software (AD Instruments, Colorado Springs, CO).
Preparation of brain tissue samples and western blot analyses.
After 7 days of icv infusion, the brains were removed, frozen on dry ice, blocked in the coronal plane, and sectioned at 100 µm thicknesses in a cryostat. The visual cortex, paraventricular hypothalamic nucleus (PVN), RVLM, and nucleus of the solitary tract (NTS) were punched out based on the technique of Palkovits and Brownstein. 15 The punch sites for each nucleus in each section were determined based on the description by Paxinos and Watson. 16 The coordinates of the punched brain regions were: PVN, 0.9-1.9 mm caudal to bregma, 0.0-0.6 mm lateral to midline, and 6.8-8.2 mm ventral to skull; NTS, 13.7-14.6 mm caudal to bregma, 0.4-1.2 mm lateral to midline, and 0.2-0.8 mm from the dorsal surface of the medulla; and RVLM, 11.8-12.7 mm posterior to bregma, 2.0-2.6 mm midline to lateral, and 2.8-3.6 mm from the dorsal surface of the medulla. Tissue samples were homogenized in RIPA buffer. Protein extracted from the homogenate was used to analyze neuronal nitric oxide synthase (nNOS) expression, using western blot. The samples were boiled for 5 min, followed by loading on a 7.5% SDS-PAGE gel (20 µg protein/30 µl/well) for electrophoresis using a Bio-Rad mini gel apparatus at 40 mA/gel for 45 min. The fractionized protein on the gel was transferred onto a polyvinyl difluoride (Millipore, Billerica, MA) and electrophoresed at 300 mA for 90 min. The membrane was probed with primary antibodies (nNOS rabbit polyclonal antibody; Santa Cruz Biotechnology, Santa Cruz, CA 1:1,000) and secondary antibody (goat anti-rabbit IgG-HRP; Santa Cruz Biotechnology, 1:2,500), and then treated with enhanced chemiluminescence substrate (Pierce, Rockford, IL) for 5 min at room temperature. The bands in the membrane were visualized and analyzed using UVP BioImaging Systems. After obtaining the nNOS blot density, the membrane was treated with Restore western Blot Stipping Buffer (Thermo Scientific, Rockford, IL) to original contributions Central AT2 Receptors and Sympathetic Outflow remove the nNOS signal, and then probed with GAPDH primary antibodies (GAPDH mouse monoclonal IgG, sc-32233; Santa Cruz Biotechnology, 1:1,000), using the same process as with the nNOS antibodies, to obtain the GAPDH blot densities. The final data reported are the nNOS band densities normalized to GAPDH.
Cell culture and patch-clamp experiments. CATH.a cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and grown in RPMI-1640 containing 8% horse serum, 4% fetal bovine serum, and 1% penicillin-streptomycin, at 37 °C in a humidified atmosphere equilibrated with 5% CO 2 . After incubation for 3-5 days, the cells were subcultured and differentiated with N 6,2′-O-dibutyryladenosine 3′,5′-monophosphate (1 mmol/l; Sigma, St Louis, MO). The differentiated CATH.a cells were then used in a series of experiments to determine the effect of C21 on delayed rectifier I Kv .
The I Kv was recorded by the whole-cell patch-clamp technique. Briefly, differentiated CATH.a cells were bathed in a solution containing (in mmol/l) NaCl 137, KCl 5.4, CaCl 2 1.35, MgSO 4 2, NaH 2 PO 4 0.3, dextrose 10, HEPES 10, pH 7.4 (NaOH) with CdCl 2 (0.3 mmol/l) and TTX (1.5 µmol/l) added to block Ca 2+ and Na + channels, respectively. The patch pipette microelectrodes were heat-polished before use, and had resistances of 3-4 MΩ when filled with an internal pipette solution containing (in mmol/l) KCl 130, CaCl 2 0.25, MgCl 2 2, ATP 1.0, GTP 0.1, EGTA 5, dextrose 8, and HEPES 10, pH 7.2 (KOH). Cell capacitance was calculated by integrating the area under the uncompensated capacitive transient evoked by a voltage step of 5 mV and dividing this area by the voltage step. All experiments were performed at room temperature (23-24 °C) using an Axopatch 200B amplifier and a Digitdata 1322A interface (Axon Instruments, Sunnyvale, CA). Cell capacitance was cancelled electronically, and the series resistance (<10 MΩ) was compensated by 75-80%. Currents were measured and analyzed using the pCLAMP 8.0 software system. Standard recording conditions for I Kv were achieved by stepping up from a holding potential of −80 to +10 mV for 300 ms. I Kv current was measured at 50 ms after the initiation of the test pulse. Current density was expressed as pA/pF.
Statistical analyses. All data are reported as the mean values ± s.e.m. A two-way analysis of variance followed by StudentNewman-Keuls was used for the statistical analysis of NE concentration, NE volume, and MAP, during both daytime and night time, from control and C21-treated rats. A paired t-test was used for statistical analysis of the difference in I Kv between each of the C21 treatment groups and the control group. A oneway analysis of variance followed by Student-Newman-Keuls was used for the statistical analysis of all other data. Statistical analysis was carried out with the aid of the SigmaPlot software. P < 0.05 was considered statistically significant. 
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Central AT2 Receptors and Sympathetic Outflow ited significantly lower NE concentrations, in both daytime and night time urine, during the 7 days following the surgery than at baseline (day 0, surgery day). This was probably related to stress. From days 3 to 7, the control group exhibited a significantly higher NE concentration in night time urine than that in daytime urine. In contrast, the C21-treated group showed no significant difference in NE concentrations between night time and daytime urine. In other words, C21 prevented nocturnal increases in NE excretion. The NE concentration values in the night time urine of C21-treated rats were lower than night time values in the controls. In effect, therefore, the NE concentration levels in the C21-treated group, both night time and daytime, were similar to the daytime concentration values in the controls. Figure 1b shows 12-h NE volume in the control and C21-treated rats. As was seen with NE concentration values, the 12-h NE volume also showed a tendency toward reduction during the night time hours after C21 infusion.
In order to explore the potential mechanisms underlying the effect of C21 on night time NE excretion, we carried out additional experiments. C21 + PD123319 and C21 + l-NAME were infused icv in separate groups of rats. Figure 1c and d shows the night time NE concentration and volume values at day 7 after treatment. Both PD123319 and l-NAME completely abolished the C21-induced decrease in NE concentration and volume. effects of c21 on arterial blood pressure Figure 2a shows the daytime and night time MAP values in controls and C21-treated rats. In both groups, there was a daily rhythmicity in values, with higher MAP at night time and lower MAP during the daytime hours. However, C21-treated rats exhibited lower MAP during both daytime and night time hours as compared to the control rats. Figure 2b shows the daytime and night time MAP at day 7 after treatment for the four groups: control, C21, C21 + PD123319, and C21 + l-NAME. Both PD123319 and l-NAME completely abolished the effect of C21 on MAP. In three different animals, we also observed the effects of PD123319 alone and l-NAME alone on MAP. PD123319 did not alter BP, but l-NAME evoked a slight, though nonsignificant, increase in BP.
effects of c21 on nnos expression Figure 3 shows nNOS protein expression in the cortex, RVLM, PVN, and NTS of brain samples from control and C21-treated rats at day 7 after treatment. There was no difference in nNOS expression between control and C21-treated rats as regards the samples from the cortex and the NTS. However, the RVLM and PVN samples from C21-treated rats exhibited significantly higher nNOS protein expression levels than those from control rats. The top panel of Figure 4 shows representative current tracings of I kv , while the bottom panel shows the group data. CATH.a neurons exhibited a small but significantly higher I Kv after C21 treatment as compared to controls, suggesting that C21 facilitates potassium channel function. In addition, the AT2R antagonist, PD123319, and the NOS blocker, l-NAME, completely abolished the effects of C21 on I Kv , demonstrating that the influence of C21 on potassium channel function was mediated by AT2R through the nitric oxide (NO) signaling pathway. PD123319 or l-NAME alone did not alter I Kv , and washout of C21 completely reversed the effects on I Kv .
discussion
Brain Ang II exhibits a marked influence on autonomic function and circulation activity. Activation of central AT1R evokes an increase in sympathetic nerve activity and BP, 17 but selective stimulation of AT2R in the RVLM evoked an effect opposite to that of AT1R. 9 In this experiment, we demonstrated that chronic icv infusion of C21, the first selective nonpeptide AT2R agonist, has a negative influence on NE excretion (a surrogate for sympathetic nerve activity) and on MAP in normal, conscious rats. We found that C21 treatment significantly decreased night time NE excretion and MAP. We further demonstrated that these inhibitory influences of C21 were completely abolished by PD123319, an AT2R antagonist, and l-NAME, a NOS inhibitor. Finally, we found that icv infusion of C21 significantly upregulated nNOS protein expression in the PVN and RVLM. These data strongly suggest a central suppressive effect of C21 on sympathetic drive and BP, mediated by AT2R through a nNOS/NO pathway. In addition, we also investigated the influence of C21 on potassium current in a neuronal cell line, the CATH.a; we found that C21 facilitates the neuronal potassium current, suggesting that C21 may have an inhibitory effect on neuronal excitability. C21 is a newly created, orally effective, nonpeptide AT2R agonist, which permits selective stimulation of the AT2R under many experimental conditions. 12 Previous experiments have demonstrated the beneficial effects of this compound in hypertension and heart failure models. In spontaneously hypertensive rats, intravenous treatment with C21 significantly decreased MAP. 12 Also, intraperitoneal injection of C21 led to a pronounced improvement in systolic and diastolic cardiac function, coinciding with a smaller scar volume in rats with permanent coronary ligation, probably through an antiapoptotic mechanism. 13 It has recently been demonstrated that C21 evokes vasorelaxation in aortas of mice and spontaneously hypertensive rats, and in the mesenteric arteries of normotensive rats; 14 this finding provides further evidence, at organ level, for the hypotensive effect of C21. The data presented in this study are the first, to our knowledge, that demonstrate a central effect of C21 on sympathetic outflow and MAP. As expected, we further found that the C21-evoked decrease in NE excretion and MAP were abolished by PD123319, demonstrating that the AT2R is the exclusive mediator of the C21 effects. It is not clear why, in normal rats, central C21 treatment suppressed only night time NE excretion while exhibiting no effects on diurnal NE excretion. Being nocturnal rodents, rats are characterized by a higher locomotor activity and sympathetic tone at night time than during the daytime. 18 We therefore assumed that the already relatively low neuronal activity during the daytime may not be further suppressed by C21. However, Takekoshi et al. 19 demonstrated that activation of the AT2R can reduce tyrosine hydroxylase activity, and consequently NE biosynthesis; this biochemical observation lends support to our findings.
Patch-clamp and extracellular single unit discharge data have demonstrated that stimulation of AT2R facilitates neuronal potassium current and decreases neuronal spontaneous discharge. Kang et al. 20 reported that activation of AT2R increased neuronal I Kv in neurons cultured from tissue specimens taken from the hypothalamus and brainstem of newborn rats. They further indicated that the third intracellular loop of the AT2R is a key component in the stimulation of neuronal I Kv elicited by activation of this receptor. 21 Martens et al. 22 documented the finding that activation of AT2R by CGP42112 modulates whole-cell K + current in the hypothalamus and brainstem of rats by increasing their open probability. Matsuura et al., 23 on the other hand, demonstrated an AT2R-mediated hyperpolarization and a decrease in the firing rate in bulbospinal RVLM neurons. These data imply that activation of AT2R facilitates potassium channel current and thereby suppresses neuronal excitability. Indeed, in our experiment we found that C21 significantly increased the neuronal potassium current in culture-grown neurons, and that this effect 
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Central AT2 Receptors and Sympathetic Outflow was completely abolished by an AT2R antagonist. These data further imply that the facilitatory influence of C21 on neuronal potassium channels may be the mechanism underlying the central effects of C21 on NE excretion and arterial pressure that we observed in our study. Matsubara 24 and Nouet 25 have suggested that there are at least three major transduction mechanisms responsible for AT2R-mediated intracellular signaling: (i) regulation of the NO-guanosine 3′,5′-cyclic monophosphate (NO-cGMP) system; (ii) stimulation of PLA2 with subsequent release of arachidonic acid; and (iii) activation of various protein phosphatases, causing protein dephosphorylation. Among these three pathways, the NO-cGMP pathway is expected to be potentially involved in the effects of AT2R on sympathetic outflow. An AT2R-coupled increase in NO generation has been found in neuronal cell lines PC12W 26 and NG-108-15. 27, 28 On the other hand, it has been shown that NO regulates several types of K + channels, including ATPdependent K + channels and Ca 2+ -activated K + channels. 29 Han et al. 30 recently reported that, in neocortical neurons from mice, low concentrations of NO donor SNAP or an NO solution had the effect of enhancing whole cell delayed rectifier K + -current (I k ) and left the fast inactivating A (I A ) current unchanged. In cell-attached experiments, a significant increase in channel open probability was observed when using low concentrations of SNAP or NO. The increase in channel activities by low concentrations of SNAP was abolished in the presence of either inhibitors of soluble guanylate cyclase or inhibitors of cGMP-dependent protein kinase G, thereby suggesting a link to the NO-cGMP signaling cascade. These results suggest that AT2R-induced activation of NO-cGMP might be responsible for the AT2R-evoked neuronal potassium current alteration. Indeed, in our experiment, we found that the l-NAME, a NOS blocker, completely abolished the C21-evoked inhibition of NE excretion and hypotension in the conscious rats, and facilitated potassium current in a neuronal cell line.
In order to determine which brain region(s) are involved in the C21 effects observed in this study, we measured nNOS protein expressions in three sympathetically relevant brain nuclei and in the cortex as a control area. We found that, nNOS expressions in the PVN and RVLM, but not in the NTS or cortex, of C21-treated rats were significantly higher than those in control rats. These data demonstrated that C21 upregulates nNOS protein expression, suggesting that activation of the NO pathway in PVN and RVLM is involved in the mechanism of suppression of NE excretion and BP by icv treatment with C21.
In summary, we found that direct central administration of C21 significantly decreases the night time NE excretion and BP in conscious, normal rats, and that these effects were completely abolished by an AT2R blocker and an NOS inhibitor. We further demonstrated that C21 increases potassium current in a neuronal cell line. These results suggest the existence of a central inhibitory influence of C21 on sympathetic outflow exclusively through AT2R, by means of an NO signaling pathway.
